Recombinant Human HLA-A*11:01 & B2M & KRAS G12A (VVVGAAGVGK) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAAGVGK peptide.
Pureté
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
Origine: Humain
Hôte: HEK-293 Cells
Recombinant
> 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.
Buffer
Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.
Stock
-20 °C,-80 °C
Stockage commentaire
-20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Date de péremption
12 months
Antigène
HLA-A*11:01
Sujet
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Poids moléculaire
50.30 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Tris-Bis PAGE result.